News mRNA COVID-19 Vaccines Not Tied to Increases in Guillain-Barré Syndrome Publish Date February 7, 2023
Drugs in the Pipeline January 2023 Recap: Drug Pipeline Updates By Brian Park, PharmD Publish Date February 1, 2023
Drugs in the Pipeline Belimumab Granted Orphan Drug Status for Systemic Sclerosis By Brian Park, PharmD Publish Date February 1, 2023
Drugs in the Pipeline Avapritinib Gets Priority Review for Indolent Systemic Mastocytosis By Brian Park, PharmD Publish Date January 23, 2023
News FDA Approves Room Temp Storage Conditions for Asceniv and Bivigam By Brian Park, PharmD Publish Date December 13, 2022
Drugs in the Pipeline September 2022 Recap: Drug Pipeline Updates By Brian Park, PharmD Publish Date October 11, 2022
Drugs in the Pipeline Leniolisib Gets Priority Review for Activated Phosphoinositide 3-Kinase Delta Syndrome By Brian Park, PharmD Publish Date September 28, 2022
News Continuation of Anti-TNF for IBD After 24 Weeks of Pregnancy Beneficial Publish Date September 27, 2022
News Reduction in Swollen, Tender Joints Greater With Litifilimab in Lupus Publish Date September 9, 2022
Drugs in the Pipeline August 2022 Recap: Drug Pipeline Update By Brian Park, PharmD Publish Date September 8, 2022
News Imbruvica Approved for Pediatric Patients With Chronic Graft-vs-Host Disease By Brian Park, PharmD Publish Date August 25, 2022
Drugs in the Pipeline Deoxycytidine Kinase Inhibitor Designated Orphan Drug for Optic Neuritis By Brian Park, PharmD Publish Date August 12, 2022
News Benlysta Approval Expanded to Include Pediatric Lupus Nephritis By Brian Park, PharmD Publish Date July 27, 2022
Drugs in the Pipeline Efzofitimod Granted Orphan Drug Status for Systemic Sclerosis By Brian Park, PharmD Publish Date April 13, 2022
News FDA Extends Shelf Life of Immune Globulin Products Asceniv and Bivigam By Brian Park, PharmD Publish Date March 30, 2022
Safety Alerts and Recalls Certain Immune Globulin Products Withdrawn Due to Higher Rate of Hypersensitivity Reactions By Brian Park, PharmD Publish Date March 9, 2022
Drugs in the Pipeline Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA By Brian Park, PharmD Publish Date January 28, 2022